Immucell (ICCC) Other Non Operating Income (2018 - 2024)
Immucell's (ICCC) quarterly Other Non Operating Income came in at -$143679.0 in Q2 2024, down 94.97% YoY from -$2.9 million in Q3 2023, and down 5.28% on a QoQ basis from -$136476.0 in Q1 2024.
Immucell (ICCC) Other Non Operating Income (2018 - 2024) Analysis & Trends
Immucell (ICCC) has 6 years of Other Non Operating Income data on file, last reported at -$143679.0 in Q2 2024.
- Quarterly Other Non Operating Income fell 94.97% year-over-year to -$143679.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was -$95731.0 (up 51.7% YoY) and the FY2025 annual result came in at $58901.0, down 49.26% from the prior year.
- Other Non Operating Income fell to -$143679.0 in Q2 2024, from -$136476.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $827690.0 in Q4 2020 to a low of -$333776.0 in Q1 2020.
- A 5-year average of -$4499.7 and a median of -$65335.5 in 2021 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2023 — Other Non Operating Income jumped 809.67% — and 2024, when it plunged 137.39%.
- Tracing ICCC's Other Non Operating Income over 5 years: stood at $827690.0 in 2020, then slumped by 70.84% to $241366.0 in 2021, then sank by 113.51% to -$32602.0 in 2022, then tumbled by 83.58% to -$59851.0 in 2023, then plunged by 140.06% to -$143679.0 in 2024.
- The last three Other Non Operating Income figures came in at -$143679.0 (Q2 2024), -$136476.0 (Q1 2024), and -$59851.0 (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Immucell | 91.19 Mn | 82.33 Mn | 2.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -143,679.00 |
| Mar 31, 2024 | -136,476.00 |
| Dec 31, 2023 | -59,851.00 |
| Sep 30, 2023 | 244,275.00 |
| Jun 30, 2023 | -73,694.00 |
| Mar 31, 2023 | -57,489.00 |
| Dec 31, 2022 | -32,602.00 |
| Sep 30, 2022 | -34,421.00 |
| Jun 30, 2022 | -63,993.00 |
| Mar 31, 2022 | -56,174.00 |
| Dec 31, 2021 | 241,366.00 |
| Sep 30, 2021 | -115,283.00 |
| Jun 30, 2021 | -74,395.00 |
| Mar 31, 2021 | -66,678.00 |
| Dec 31, 2020 | 827,690.00 |
| Sep 30, 2020 | -71,290.00 |
| Jun 30, 2020 | -74,524.00 |
| Mar 31, 2020 | -333,776.00 |
| Jun 30, 2018 | -75.00 |
| Mar 31, 2018 | 75.00 |